Mohamed Rezk1, Ragab Dawood1, Mohamed Abo-Elnasr1,2, Alaa Al Halaby1, Hala Marawan3. 1. a Department of Obstetrics and Gynecology, Faculty of Medicine , Menoufia University , Menoufia , Egypt . 2. b Department of Obstetrics and Gynecology, Faculty of Medicine , Taibah University , Madina , Saudi Arabia , and. 3. c Department of Community Medicine and Public Health, Faculty of Medicine , Menoufia University , Menoufia , Egypt.
Abstract
OBJECTIVE: This study was conducted to evaluate the efficacy and safety of lactoferrin in comparison to ferrous sulphate for the treatment of iron deficiency anemia (IDA) during pregnancy. MATERIALS AND METHODS: This prospective, randomized, parallel-group, single-center study was conducted in the Department of Obstetrics and Gynecology at Menoufia University Hospital, Egypt and included a total of 200 pregnant women in the second trimester with IDA who were enrolled and randomly assigned either to receive 150 mg of dried ferrous sulphate capsules or lactoferrin 250 mg capsules once daily for eight consecutive weeks. The primary efficacy parameter was the amount of increase in hemoglobin concentration by 4 and 8 weeks, the adverse effects related to iron therapy and the patient compliance to the treatment. RESULTS:Total increase in Hb after 2 months with lactoferrin was higher (2.26 ± 0.51 g/dL) compared to ferrous sulfate (1.11 ± 0.22 g/dL) (p < 0.001). Gastrointestinal adverse events occurred more frequently with ferrous sulphate than the lactoferrin group (p < 0.001). The number of women requesting change the drug was higher in the ferrous sulphate group (p < 0.001). CONCLUSION:Lactoferrin was more effective than ferrous sulfate over a two-month period in pregnant women with IDA, with fewer gastrointestinal adverse events and better treatment acceptability.
RCT Entities:
OBJECTIVE: This study was conducted to evaluate the efficacy and safety of lactoferrin in comparison to ferrous sulphate for the treatment of iron deficiency anemia (IDA) during pregnancy. MATERIALS AND METHODS: This prospective, randomized, parallel-group, single-center study was conducted in the Department of Obstetrics and Gynecology at Menoufia University Hospital, Egypt and included a total of 200 pregnant women in the second trimester with IDA who were enrolled and randomly assigned either to receive 150 mg of dried ferrous sulphate capsules or lactoferrin 250 mg capsules once daily for eight consecutive weeks. The primary efficacy parameter was the amount of increase in hemoglobin concentration by 4 and 8 weeks, the adverse effects related to iron therapy and the patient compliance to the treatment. RESULTS: Total increase in Hb after 2 months with lactoferrin was higher (2.26 ± 0.51 g/dL) compared to ferrous sulfate (1.11 ± 0.22 g/dL) (p < 0.001). Gastrointestinal adverse events occurred more frequently with ferrous sulphate than the lactoferrin group (p < 0.001). The number of women requesting change the drug was higher in the ferrous sulphate group (p < 0.001). CONCLUSION: Lactoferrin was more effective than ferrous sulfate over a two-month period in pregnant women with IDA, with fewer gastrointestinal adverse events and better treatment acceptability.
Entities:
Keywords:
Ferrous sulphate; iron deficiency anemia; lactoferrin; pregnant women
Authors: Santiago Presti; Sara Manti; Giuseppe Fabio Parisi; Maria Papale; Ignazio Alberto Barbagallo; Giovanni Li Volti; Salvatore Leonardi Journal: J Clin Med Date: 2021-11-23 Impact factor: 4.241
Authors: Thomas P Hopp; Klaudyna Spiewak; Maura-Ann H Matthews; Zafeiria Athanasiou; Richard S Blackmore; Gary A Gelbfish Journal: PLoS One Date: 2022-05-19 Impact factor: 3.240